你是否曾经好奇过，为什么我们每年都要接种流感疫苗？而如今，一种新的呼吸道合胞病毒（RSV）疫苗正在悄然改变这一现状。最近，三叶草生物-B(02197.HK)宣布其二价RSV候选疫苗SCB-1019在与GSK的AREXVY疫苗进行头对头比较时，取得了令人瞩目的积极结果。这究竟意味着什么？让我们一起揭开这个谜底。 想象一下，在一个寒冷的冬日，你的孩子突然开始咳嗽、发烧，医生告诉你这是RSV感染。这种病 ...

【财华社讯】三叶草生物-B (02197.HK)公布，在Ⅰ期临床试验中评估未使用佐剂的二价RSV PreF-三聚体亚单位候选疫苗SCB-1019 ...

The fusion of an ovum and a sperm relies on processes that remain largely unknown. But today, researchers have identified a ...

Clover announces positive clinical data for RSV vaccine candidate SCB-1019 compared head-to-head versus GSK’s Arexvy: Shanghai Wednesday, October 30, 2024, 17:00 Hrs [IST] Clove ...

Under certain conditions, SOD1 will change its shape and reassemble itself into a three-unit form called a trimer. "We need to understand how the SOD1 trimers kill cells and the mechanisms ...

trial evaluating SCB-1019 – the company's non-adjuvanted bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate based on Clover's Trimer-Tag vaccine technology platform ...